Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Nursing December 2009 Vincent M. Vacca	On the Alert for Pulmonary Arterial Hypertension Progressive and ultimately fatal, pulmonary arterial hypertension is a disease of the pulmonary arterial vasculature with no known cause.
Nurse Practitioner February 2011 Jennifer M. Belavic	Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available.
American Family Physician May 1, 2001 Trenton D. Nauser & Steven W. Stites	Diagnosis and Treatment of Pulmonary Hypertension Regardless of the etiology, unrelieved pulmonary hypertension can lead to right-sided heart failure. Signs and symptoms of pulmonary hypertension are often subtle and nonspecific...
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
The Motley Fool May 28, 2009 Robert Steyer	Fighting an Incurable Disease United Therapeutics battles drug giants in a specialized blood-pressure treatment arena.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
The Motley Fool December 17, 2010 Brian Orelli	An Overnight Double: Santa Visits InterMune in Europe The Committee for Medicinal Products for Human Use issued a positive recommendation for the approval of InterMune's idiopathic pulmonary fibrosis treatment, Esbriet, sending shares up 140%.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
The Motley Fool February 18, 2005 Charly Travers	A Drug to Get Your Blood Pumping Encysive's Thelin combines low risk with high sales potential.
The Motley Fool June 18, 2007 Brian Lawler	Gilead Gets the Payoff Gilead gets marketing approval for one of its drug candidates. Investors, take note.
The Motley Fool August 2, 2007 Brian Lawler	United Therapeutics Unites R and D The drugmaker quietly beats the market while vying for its share of customers. Investors, take note.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.
The Motley Fool January 28, 2008 Brian Lawler	Can Encysive Catch the Competition? After two years of spectacular mismanagement, will 2008 be the year that Encysive Pharmaceuticals is finally able to capitalize on its very marketable lead drug, Thelin?
Pharmaceutical Executive June 1, 2014 O'Connor et al.	Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs.
The Motley Fool December 7, 2006 Brian Lawler	The Best Small Cap for 2007: Encysive Pharmaceuticals This little drug maker has the potential for big profit, in both the U.S. and Europe. Investors, take note.
American Family Physician May 1, 2001	Pulmonary Hypertension Pulmonary hypertension happens when the blood pressure in the pulmonary arteries (the vessels that carry blood from the heart to the lungs) becomes higher than normal. This puts strain on the right side of the heart. Pulmonary hypertension is a serious problem...
The Motley Fool November 22, 2006 Brian Lawler	Actelion's Adept Acquisition The pharmaceutical buys CoTherix, streamlining sales of both firms' PAH treatments. Investors, take note.
The Motley Fool December 12, 2005 Stephen D. Simpson	Heavy Breathing for Myogen Positive data from a phase 3 drug study sends shares of this biotech much higher.
American Family Physician September 1, 2003 Magill et al.	New Developments in the Management of Hypertension Advances in the management of hypertension have refined our understanding of systolic blood pressure, nutrition, medication selection, and hypertension in special populations.
Chemistry World September 20, 2006 Victoria Gill	`Silent Killer' as Treatment for Heart and Lung Disease Carbon Monoxide (CO), a gas once dubbed the `silent killer' by the UK's health and safety executive, could provide a life-saving treatment for an incurable lung and heart condition, report researchers.
The Motley Fool September 14, 2006 Brian Lawler	Good Buy for Biogen Idec The biotech's past success bodes well for its plans for a new blood pressure drug. Investors, take note.
The Motley Fool August 4, 2005 Charly Travers	This One's a Winner Encysive awaits FDA approval, and all signs are positive. Biotech investors, take note.
The Motley Fool May 26, 2009 Brian Orelli	Will the FDA Approve These Drugs? Plenty of Prescription Drug User Fee Act dates are right around the corner. Read on to see which pharma companies may be affected.
The Motley Fool August 7, 2007 Brian Lawler	Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential.
American Family Physician August 1, 2002 Mark W. Niedfeldt	Managing Hypertension in Athletes and Physically Active Patients Athletes and other physically active patients should be screened for hypertension and given appropriate therapy if needed.
The Motley Fool September 6, 2007 Brian Lawler	Encysive, Please Stop Its failure to acquiesce to the FDA's request means the competition is going forward as this drugmaker's product stays stagnant. Investors, take note.
The Motley Fool February 21, 2007 Brian Lawler	Gilead Closes the Gap The FDA trims Gilead's review period for a top developmental compound. Investors, take note.
The Motley Fool February 22, 2008 Brian Lawler	The Hypertension Fight Expands News from the pharmaceutical industry regarding hypertension medications: Gilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
American Family Physician April 15, 2005 Karnani, Reisfield & Wilson	Evaluation of Chronic Dyspnea Chronic dyspnea is defined as dyspnea lasting more than one month. Information is presented on diagnosis, assessment and treatment for chronic dyspnea.
The Motley Fool April 3, 2009 Brian Orelli	Gilead: Helping Investors Cope With the Market Diversifying seems to be paying off for the drugmaker.
The Motley Fool June 2, 2006 Brian Lawler	Encysive Can Breathe Easier The pharmaceutical's crucial Thelin drug gains EU approval. Encysive's next critical hurdle lies here in the U.S. Whatever the FDA's decision, expect more volatility in Encysive shares.
The Motley Fool May 30, 2008 Brian Lawler	Gilead Gets Synergistic Gilead Sciences newly acquired compound will play nicely with the drugmaker's existing products.
American Family Physician January 15, 2004 Mark H. Ebell	Suspected Pulmonary Embolism: Part I How can the history and physical examination help physicians diagnose pulmonary embolism?
The Motley Fool May 11, 2006 Brian Lawler	Encysive Evasive About Thelin The pharmaceutical stays tight-lipped about FDA approval of its new drug. Investors should keep an eye on Encysive's cash-burn rate in the coming months.
The Motley Fool March 28, 2008 Brian Lawler	Pfizer Gets the Signal to Steal Pfizer's acquisition of Encysive Pharmaceuticals is set for Monday.